fb-PMT

fb-PMT is a synthetic small molecule and potent antagonist of the thyrointegrin αvβ3 receptor, developed for its antiangiogenic and anticancer properties. It consists of triAzole tetraiodothyroacetic acid (TAT) conjugated to polyethylene glycol with a lipophilic 4-fluorobenyl group, which enables high-affinity (0.21 nM) and specific binding to the αvβ3 integrin on cancer cells and rapidly dividing endothelial cells. Unlike non-polymer conjugated TAT, it does not translocate to the nucleus but acts at the cell surface. Preclinical studies have shown that fb-PMT inhibits tumor growth, angiogenesis, and cell viability in glioblastoma models by interfering with multiple key signaling pathways essential for tumor progression and vascularization. The drug also demonstrates effective transport across the blood-brain barrier via high-affinity binding to plasma transthyretin (TTR), resulting in high retention within brain tumors[1][3][4]. It is being investigated primarily for recurrent glioblastoma but has also been studied in other cancers such as acute myeloid leukemia and pancreatic cancer[4][5].

Other names

thyrointegrin alphaVbeta3 antagonist fb-PMTalphaV/beta3 antagonist fb-PMTfluorobenzyl polyethylene glycol-conjugated tetraiodothyroacetic acid